Regulation & Approvals
Biocomposites Welcomes Wounds UK Guidance on Osteomyelitis in Severe Pressure Ulcers
By News Desk ·
Key takeaways
- Wounds UK published a Best Practice Statement, Osteomyelitis in pressure ulcers, with a structured assessment pathway for sacral pressure ulcers.
- A Wounds UK expert meeting report in Volume 22, Issue 4 recommends STIMULAN with antibiotics in appropriately selected patients.
- Biocomposites' STIMULAN Rapid Cure and STIMULAN Kit received EU MDR certification in February 2026.
Biocomposites welcomed new Wounds UK clinical guidance on osteomyelitis in severe pressure ulcers, including a structured assessment pathway and recommendations for using STIMULAN with antibiotics, the company said in a GlobeNewswire announcement on November 17, 2026. The Keele, United Kingdom-based Biocomposites engineers, manufactures and markets products for infection management in bone and soft tissue.
What the Wounds UK Guidance Covers
The independently developed Best Practice Statement, Osteomyelitis in pressure ulcers, sets out a structured pathway for assessing and managing osteomyelitis in sacral pressure ulcers. The pathway covers patient assessment, identification of infection, treatment decisions and ongoing management, including consideration of local antibiotic treatment as part of individualised care.
A companion Wounds UK expert meeting report, Local Infection Management in Pressure Ulcers, was published in Wounds UK Volume 22, Issue 4 on pages 29-33. The report offers practical recommendations for using STIMULAN with antibiotics in appropriately selected patients with severe pressure ulcers and follows a May 2026 advisory board meeting of UK wound care specialists. Its pathway outlines a step-by-step approach to using STIMULAN with antibiotics, covering selection, prescribing, application and monitoring, and emphasises coordination between acute and community care teams.
Jacqui Fletcher OBE, an independent nurse consultant, said: "Clear clinical pathways can help healthcare professionals navigate assessment and treatment decisions more consistently, supporting earlier intervention, appropriate patient selection and coordinated, patient-centred care."
Davina Lawrence, National Sales Director of Biocomposites, said: "We welcome this independent clinical pathway as an important step towards more consistent, proactive treatment of osteomyelitis in severe pressure ulcers."
STIMULAN is an absorbable calcium matrix designed to deliver antibiotics locally to assist in the management of infection in bone and surrounding soft tissue. Pressure ulcers cost the NHS in England approximately £3.8 million every day, according to a 2018 estimate by NHS Improvement cited in the announcement.
Biocomposites' STIMULAN Regulatory Record
According to akta.pro company records, Biocomposites secured EU MDR certification in February 2026 for STIMULAN Rapid Cure and STIMULAN Kit, making them the only certified calcium matrix antibiotic carriers for combining Gram-positive and Gram-negative antibiotics. The same records show the company received a £1.7m grant from the UK government's Life Sciences Innovative Manufacturing Fund in February 2026 to expand manufacturing at Keele's Science and Innovation Park, primarily to scale STIMULAN production. Biocomposites products are used in over 1 million procedures per annum and sold in more than 100 countries, according to the announcement.
Wounds UK Conference Session
The themes in the guidance were explored at Biocomposites' industry symposium, Local Infection Management in Pressure Ulcers: A New Paradigm for Tissue Viability, at the 2026 Wounds UK Conference in Harrogate from 9-11 November. The session brought together clinical experts to discuss early intervention, multidisciplinary treatment pathways and practical experience with local antibiotic delivery.